论文部分内容阅读
目的:探讨重组人干扰素α-2b凝胶联合氯喹那多-普罗雌烯阴道片治疗慢性宫颈炎并阴道高危型人乳头状瘤病毒感染的临床疗效。方法:选择2013年5月至2016年7月我院收治的120例慢性宫颈炎并阴道高危型人乳头状瘤病毒感染患者作为此次研究对象,随机将患者分为对照组及治疗组,对照组应用氯喹那多-普罗雌烯阴道片治疗,治疗组应用重组人干扰素α-2b凝胶联合氯喹那多-普罗雌烯阴道片治疗,比较两组患者的临床疗效。结果:对照组人乳头瘤状病毒转阴率是18.33%,治疗总有效率是83.3%;治疗组人乳头瘤状病毒转阴率是38.33%,治疗总有效率是96.7%。组间对比具有显著差异(P<0.05)。结论:阴道高危型人乳头状瘤病毒感染应用重组人干扰素α-2b凝胶联合氯喹那多-普罗雌烯阴道片治疗能够获得显著临床疗效,值得推广。
Objective: To investigate the clinical efficacy of recombinant human interferon α-2b gel combined with chloroquine-dopa vaginal tablets in the treatment of chronic cervicitis and high risk of human papillomavirus infection. Methods: From May 2013 to July 2016 in our hospital, 120 cases of chronic cervicitis and high risk of human papillomavirus infection of the vagina were selected as the research object, the patients were randomly divided into control group and treatment group, control The patients in the treatment group were treated with chloroquine-proestrogen vaginal tablets. The patients in the treatment group were treated with recombinant human interferon alpha-2b gel combined with chloroquine-dopa vaginal tablets. The clinical efficacy of the two groups was compared. Results: The negative rate of human papillomavirus in control group was 18.33%, the total effective rate was 83.3%. The negative rate of HPV in treatment group was 38.33%, and the total effective rate was 96.7%. There was significant difference between groups (P <0.05). Conclusion: The treatment of vaginal high-risk human papillomavirus infection with recombinant human interferon α-2b gel combined with chloroquinendo-proestradiol vaginal tablets can achieve significant clinical efficacy, which is worth promoting.